No Data
Viatris Inc's Dividend Analysis
Regeneron Wins Temporary Restraining Order Preventing Eylea Generics
8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard
About 70% of S&P 500 Names Beat EPS, While 47% Soar Past Revenue Estimates This Week - Earnings Scorecard
Viatris Inc. (VTRS) Q1 2024 Earnings: Aligns With EPS Projections Amidst Strategic Shifts and ...
UBS Trims Viatris Price Target to $12 From $13, Maintains Neutral Rating
Viatris (VTRS) has an average rating of Hold and price targets ranging from $11 to $14, according to analysts polled by Capital IQ. Price: 11.19, Change: -0.03, Percent Change: -0.27